TNFRSF11A and plasma cell myeloma: Pearse et al. have demonstrated that administration of RANK-Fc in a SCID-hu murine model of human myeloma caused a reduction in serum paraprotein as well as a reduction in tumor burden [32], arguing for a direct anti-myeloma effect.